Endocrine Fellows: T1DM 2021 Diagnosing and Understanding Risks of T1D
Endocrine Fellows: T1DM 2021 Diagnosing and Understanding Risks of T1D
T1D Fellows Program On-Demand Courses
Keynote: Looking Back at 100 Years of Insulin
Diagnosing and Understanding Risks of T1D
Principles in Insulin and Emerging Non-Insulin Therapies
Closing the Loop with Diabetes Technology
Screening, Preventing, and Treating Vascular Disease
Addressing Depression in T1D and Challenges across the Lifespan
Nutrition and Exercise in T1D Management
Caring for the Sick Patient at Home and in Emergency Situations
Irl B. Hirsch, MD, University of Washington School of Medicine
Davida F. Kruger, MSN, APN-BC, BC-ADM, Henry Ford Health System
Luisa Duran, MD, John Muir Health
Robert H. Eckel, MD, University of Colorado
Alison B. Evert, MS, RD, CDE, University of Washington
Satish Garg, MD, Barbara Davis Center
Janet B. McGill, MD, MA, FACE, Washington University in St. Louis
Michael C. Riddell, PhD, York University
Elizabeth Seaquist, MD, University of Minnesota
Jennifer Sherr, MD, PhD, Yale School of Medicine
Linda M. Siminerio, RN, PhD, CDE, University of Pittsburgh
Jill A. Weissberg-Benchell, PhD, CDE, Northwestern University
Jay S. Skyler, MD, University of Miami
STATEMENT OF INDEPENDENCE
As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society's Special Programs Committee (SPC). The commercial supporter(s) of this activity have no influence over the planning of this CME activity.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Irl B. Hirsch, MD (Co-Chair), has served as a research investigator for Beta Bionics, Medtronic Diabetes and Insulet and as a consultant/advisory board for Abbot Diabetes Care and Big Foot Biomedical.
Davida F. Kruger, MSN, APN-BC, BC-ADM (Co-Chair), has served on advisory boards and/or speaker bureaus for Abbott Diabetes Care, Dexcom, Eli Lilly and Company, Novo Nordisk, Pendulum Life, sanofi-aventis U.S. LLC, and Xeris.
Robert H. Eckel, MD, has served as a consultant and/or advisory board member to Kaleido Biosciences, Kowa American Corp., and Provention Bio, Inc.
Satish Garg, MD, has served on the advisory board for Novo Nordisk, Inc., Zealand, Medtronic, and Eli Lilly.
Janet B. McGill MD, MA, has received grant funding from Dexcom, Medtronic, and Novo Nordisk; has served as a consultant and/or advisory board for Bayer, Boehringer Ingelheim, Dexcom, Lilly, Metavant, Salix.
Anne L. Peters, MD, has served on an advisory board for Abbot Diabetes Care, Eli Lilly, Medscape, Merck, Novo Nordisk, Zealand; lecturer for Biorad; and received research funding from Dexcom.
Michael C. Riddell, PhD, has served as a consultant for Insulet Corporation, advisory board for Zucara Theraputics, received honoraria for Speakers' Bureau for Novo Nordisk, Eli Lilly, and Sanofi.
Jennifer Sherr, MD, PhD, has served as a consultant and/or advisory board member for Insulet, Lexicon, Bigfoot Biomedical, Cecelia Health and received research support from Medtronic Diabetes, Lilly Diabetes
Linda M. Siminerio, RN, PhD, CDE, has received research support from Becton Dickinson and Sanofi, and served on the advisory board for Abbott and Bayer.
The following faculty reported no relevant financial relationship: Luisa Duran, MD, Alison B. Evert, MS, RD, CDE, Elizabeth Seaquist, MD, and Jill A. Weissberg-Benchell, PhD, CDE, Jay S. Skyler, MD.
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.
Use of professional judgment:
The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.
Drugs and dosages:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.
POLICY ON UNLABELED/OFF-LABEL USE
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.
PRIVACY AND CONFIDENTIALITY STATEMENT
The Endocrine Society will record learner's personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.
This education activity is supported by an independent medical educational grant from Abbott Diabetes Care, Inc., Dexcom, Inc., Helmsley Charitable Trust, Insulet Corporation, Lilly USA, Medtronic Diabetes, and Tandem Diabetes Care.